USFDA finds adulteration, 'significant violations' at Strides Pharma plant


The US Food and Drug Administration (FDA) has raised doubts about Strides Pharma Sciences Ltd's quality-control practices after finding adulteration and evidence of "uncontrolled shredding of documents" at one of its plants.

The FDA found "significant violations" of current good manufacturing practice (CGMP) regulations at Strides Pharma's plant in Puducherry in southern India, the drug regulator said in a warning letter that was made public on Tuesday. Shares of the Bangalore-based company, which fell.....

This article is no longer available in our repository.

There could be multiple reasons for this.